BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 18, 2026
See today's BioWorld Asia
Home
» More Japan troubles as Novartis faces possible suspension
To read the full story,
subscribe
or
sign in
.
More Japan troubles as Novartis faces possible suspension
Feb. 4, 2015
By
Alfred Romann
HONG KONG – Novartis AG faces a new series of challenges in Japan that stem from a failure to notify authorities of serious side effects associated with two dozen of its drugs.
BioWorld Asia